Sugi Predict

Sugi Predict / Targets / CCR7

CCR7

C-C chemokine receptor type 7 · P32248 · CCR7 on Sugi Atlas →

6,000 patent compounds predicted against CCR7, 4,271 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5193193 SCHEMBL5193193 0.47 8/20
SCHEMBL3852998 SCHEMBL3852998 0.44 8/20
SCHEMBL490245 SCHEMBL490245 0.50 7/20
SCHEMBL3860775 SCHEMBL3860775 0.45 7/20
SCHEMBL3851948 SCHEMBL3851948 0.44 7/20
SCHEMBL3851449 SCHEMBL3851449 0.64 6/20
SCHEMBL3857366 SCHEMBL3857366 0.44 6/20
SCHEMBL3856241 SCHEMBL3856241 0.42 6/20
SCHEMBL5191087 SCHEMBL5191087 0.41 6/20
SCHEMBL3854713 SCHEMBL3854713 0.66 5/20
SCHEMBL3851505 SCHEMBL3851505 0.65 5/20
SCHEMBL3861386 SCHEMBL3861386 0.62 5/20
SCHEMBL3857794 SCHEMBL3857794 0.56 5/20
SCHEMBL3857750 SCHEMBL3857750 0.51 5/20
SCHEMBL3852321 SCHEMBL3852321 0.50 5/20
SCHEMBL3849120 SCHEMBL3849120 0.49 5/20
SCHEMBL3851525 SCHEMBL3851525 0.49 5/20
SCHEMBL3853004 SCHEMBL3853004 0.48 5/20
SCHEMBL3852787 SCHEMBL3852787 0.43 5/20
SCHEMBL3856689 SCHEMBL3856689 0.43 5/20

Clinical trials — most relevant to CCR7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Quantitating the Impact of Plerixafor PHASE1/PHASE2UNKNOWN
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) PHASE1RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation PHASE1RECRUITING
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation nanCOMPLETED
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder nanUNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Lung-Resident Memory Th2 Cells in Asthma nanACTIVE_NOT_RECRUITING
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Influence of Extracorporeal Photopheresis on Skin Sclerosis nanCOMPLETED
The Relationship Between Serum Chemokine Ligand 21 (CCL-21) Level and Disease Activity nanNOT_YET_RECRUITING
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
Hepatitis C Virus and the Humoral Immune System nanCOMPLETED
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
Non Primary HCMV Infection: Natural History and Immune Response nanACTIVE_NOT_RECRUITING
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy nanCOMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Role of Chemokine and Chemokine Receptor in Psoriasis nanWITHDRAWN
Activation and Recruitment of GIL During Hp Infection nanUNKNOWN
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCR7 binder may also engage these)

ProteinNameSimilarity
Q5MD62 — 1.000 Q5MD62 →
P47774 — 1.000 P47774 →
Q95ND1 — 0.996 Q95ND1 →
P61815 — 0.995 P61815 →
CXCR2 C-X-C chemokine receptor type 2 0.995 landscape →
P56439 — 0.994 P56439 →
CCR8 C-C chemokine receptor type 8 0.994 landscape →
Q9TV48 — 0.994 Q9TV48 →
Q95NE8 — 0.994 Q95NE8 →
O97962 — 0.994 O97962 →
Q9EQ16 — 0.994 Q9EQ16 →
O97880 — 0.994 O97880 →
CCR4 C-C chemokine receptor type 4 0.993 landscape →
P61755 — 0.993 P61755 →
O19024 — 0.993 O19024 →
O97571 — 0.993 O97571 →
P56482 — 0.993 P56482 →
P61757 — 0.992 P61757 →
O97879 — 0.992 O97879 →
O97883 — 0.992 O97883 →
CCR1 C-C chemokine receptor type 1 0.992 landscape →
P70612 — 0.992 P70612 →
O97881 — 0.992 O97881 →
Q9TV49 — 0.991 Q9TV49 →
Q9XT76 — 0.991 Q9XT76 →
A6QNL7 — 0.991 A6QNL7 →
P51683 — 0.991 P51683 →
Q95NC3 — 0.990 Q95NC3 →
O54689 — 0.990 O54689 →
Q2KTE1 — 0.990 Q2KTE1 →